NASDAQ:BLPH - Bellerophon Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 1,266.91 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.39
▲ +0.11 (8.59%)

This chart shows the closing price for BLPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bellerophon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLPH

Analyst Price Target is $19.00
▲ +1,266.91% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Bellerophon Therapeutics in the last 3 months. The average price target is $19.00, with a high forecast of $19.00 and a low forecast of $19.00. The average price target represents a 1,266.91% upside from the last price of $1.39.

This chart shows the closing price for BLPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Bellerophon Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2022Brookline Capital AcquisitionLower Price Target$26.00 ➝ $19.00Low
4/4/2022Brookline Capital ManagementLower Price Target$26.00 ➝ $19.00Low
11/16/2021HC WainwrightReiterated RatingBuyHigh
6/23/2021Brookline Capital ManagementReiterated RatingBuyMedium
11/6/2020Maxim GroupReiterated RatingBuy$22.00Medium
8/11/2020Jefferies Financial GroupInitiated CoverageBuy$19.00Medium
8/6/2020HC WainwrightReiterated RatingBuy$30.00High
5/14/2020Maxim GroupReiterated RatingBuy$30.00Medium
4/14/2020Brookline Capital ManagementInitiated CoverageBuy$35.00Low
2/18/2020HC WainwrightReiterated RatingBuy$30.00High
12/18/2019HC WainwrightReiterated RatingBuy$45.00Low
11/7/2019Maxim GroupReiterated RatingBuy$30.00Low
8/9/2019Maxim GroupReiterated RatingBuy$30.00Low
4/8/2019Maxim GroupSet Price TargetBuy$45.00Low
1/29/2019HC WainwrightReiterated RatingBuy$45.00Low
1/24/2019Maxim GroupInitiated CoverageBuy ➝ Buy$45.00High
8/9/2018HC WainwrightReiterated RatingBuy$45.00Medium
8/2/2018HC WainwrightReiterated RatingBuy$75.00Low
5/11/2018HC WainwrightReiterated RatingBuyLow
3/20/2018HC WainwrightReiterated RatingBuyMedium
9/6/2017HC WainwrightReiterated RatingBuy$75.00Low
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/14/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/13/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Bellerophon Therapeutics logo
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Read More

Today's Range

Now: $1.39
Low: $1.28
High: $1.48

50 Day Range

MA: $1.23
Low: $0.86
High: $1.69

52 Week Range

Now: $1.39
Low: $0.67
High: $4.49

Volume

30,672 shs

Average Volume

20,659 shs

Market Capitalization

$13.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bellerophon Therapeutics?

The following sell-side analysts have issued research reports on Bellerophon Therapeutics in the last twelve months: Brookline Capital Acquisition Corp., Brookline Capital Management, HC Wainwright, and StockNews.com.
View the latest analyst ratings for BLPH.

What is the current price target for Bellerophon Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Bellerophon Therapeutics in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 1,266.9%. Brookline Capital Acquisition Corp. has the highest price target set, predicting BLPH will reach $19.00 in the next twelve months. Brookline Capital Acquisition Corp. has the lowest price target set, forecasting a price of $19.00 for Bellerophon Therapeutics in the next year.
View the latest price targets for BLPH.

What is the current consensus analyst rating for Bellerophon Therapeutics?

Bellerophon Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLPH will outperform the market and that investors should add to their positions of Bellerophon Therapeutics.
View the latest ratings for BLPH.

What other companies compete with Bellerophon Therapeutics?

How do I contact Bellerophon Therapeutics' investor relations team?

Bellerophon Therapeutics' physical mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company's listed phone number is (908) 574-4770 and its investor relations email address is [email protected] The official website for Bellerophon Therapeutics is www.bellerophon.com. Learn More about contacing Bellerophon Therapeutics investor relations.